PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjopthalBritish Journal of OphthalmologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Br J Ophthalmol. 2007 July; 91(7): 916–921.
Published online 2007 January 17. doi:  10.1136/bjo.2007.114801
PMCID: PMC1955648

Outcome of phacoemulsification in patients with uveitis

Abstract

Aims

To examine the visual outcome and identify risk factors for postoperative uveitis, macular oedema and neodymium‐doped yttrium aluminium garnet (Nd:YAG) capsulotomy after phacoemulsification and intraocular lens (IOL) implantation in patients with uveitis.

Method

This is a retrospective review of the medical records of 101 eyes of 101 patients. One eye was randomly selected for inclusion in patients who had bilateral surgery. Patients with juvenile arthritis, keratouveitis and lymphoma‐associated uveitis were excluded.

Results

At the first postoperative and final visits, visual acuity was significantly better (p<0.001), and 64.4% and 71.3% of patients, respectively, had achieved [gt-or-equal, slanted]2 Snellen's lines of visual improvement. The cumulative probability of doubling of the visual angle was 52% over 6 years of follow‐up, and this occurred at a higher rate in the presence of preoperative retinal or optic nerve lesions (HR (95% CI) 4.49 (1.41 to 14.29)). Within 3 months after operation, uveitis was more likely to develop in female patients (OR (95% CI) 6.21 (1.41 to 27.43)) and in the presence of significant intraoperative posterior synechiae (OR (95% CI) 8.43 (1.09 to 65.41)); macular oedema was more likely to develop in patients who developed postoperative uveitis (OR (95% CI) 7.45 (1.63 to 34.16)). Nd:YAG capsulotomy occurred at a higher rate in patients aged [less-than-or-eq, slant]55 years (HR (95% CI) 2.28 (1.06, 4.93)) and in those with hydrogel IOLs (HR (95% CI) 3.71 (1.04 to 13.20)), and occurred at a lower rate in patients who had prophylactic systemic corticosteroids (HR (95% CI) 0.25 (0.11 to 0.59)), with plate‐haptic silicone IOLs (HR (95% CI) 0.23 (0.08 to 0.64)) and three‐piece silicone IOLs (HR (95% CI) 0.19 (0.05 to 0.74)) in comparison to those with polymethylmethacrylate IOLs.

Conclusion

Most patients with uveitis achieve improved visual acuity after phacoemulsification, but an increasing rate of visual loss is observed in those with pre‐existent macular or optic nerve lesions. Identifying patients who are at risk of postoperative complications should help in patient counselling and to pre‐empt these complications by using preoperative prophylactic corticosteroids, careful IOL selection and postoperative intensive corticosteroids.

Cataract occurs in up to 50% of patients with uveitis. In these patients, the visual outcome of cataract extraction can be unpredictable and can lead to a higher rate of postoperative inflammation, macular oedema1,2,3,4,5,6,7,8 and posterior capsular opacification (PCO)9 than in patients without uveitis.

Little is known about the factors that could affect the visual outcome or the development of postoperative complications. Several studies have established a relationship between factors such as age, race, gender and coexistent systemic diseases, and the long‐term visual outcome in these patients.10,11 It is not known whether these factors can also affect the postoperative course and the long‐term visual outcome after cataract extraction.

This retrospective study was carried out to examine the visual outcome after phacoemulsification in patients with uveitis, and the rate and risk factors for visual loss, development of postoperative uveitis, macular oedema and PCO.

Materials and methods

We reviewed the medical records of 156 patients with uveitis who had undergone phacoemulsification cataract surgery and intraocular lens (IOL) implantation at Moorfields Eye Hospital, Whipps Cross University Hospital (London, UK) the Royal Prince Alfred Hospital, or St Vincent's Hospital (Sydney, New South Wales, Australia) between 1996 and 2001. All three hospitals used similar protocols for perioperative management of patients with cataract and uveitis.

Inclusion and exclusion criteria

All patients with a minimum follow‐up of 3 months (n = 151 eyes) were eligible for inclusion, but only the first eye of those who underwent bilateral surgery (n = 36) was included. Patients with juvenile idiopathic arthritis who had lensectomy (n = 2), those with herpetic keratouveitis (n = 4) or lymphoma‐associated uveitis (n = 2) and those who underwent phacotrabeculectomy (n = 6) were excluded. These patients either had different perioperative treatment regimens or had visual loss due to causes other than those related to uveitis.

Data retrieval

The data retrieved from the clinical notes included gender, age at surgery, type of uveitis, presence of a uveitis‐associated systemic disease, surgical details and postoperative complications, and preoperative and postoperative best‐corrected visual acuity (BCVA). The postoperative BCVA was taken at the first postoperative visit (within 48 h) and final visit. Snellen's acuity was converted into the log minimum angle of resolution (logMAR) equivalent for statistical analysis.

Diagnosis of uveitis and associated systemic and ocular diseases

The classification of uveitis diagnoses followed the International Uveitis Study Group classification of uveitis.12 A total of 57 (56%) patients had anterior uveitis which comprised three subgroups: recurrent acute anterior uveitis (n = 25, 43.9%); chronic anterior uveitis (n = 22, 38.6%); and Fuchs' heterochromic cyclitis (n = 10, 17.5%). A total of 44 (44%) patients had posterior uveitis which comprised two subgroups: intermediate uveitis (n = 17, 39%) and posterior uveitis (n = 27, 61%). The second subgroup included patients with chorioretinitis, retinal vasculitis or panuveitis.

Uveitis‐associated systemic disease was present in 25 (24.8%) patients (table 11).). Eight patients had diabetes mellitus but none of them had clinically significant retinopathy. One patient had had a trabeculectomy for chronic glaucoma 5 years before operation, and another had had pars plana vitrectomy for rhegmatogenous retinal detachment 18 months before operation.

Table thumbnail
Table 1 Patient characteristics

Macular and/or optic nerve lesions were present in 21 (20.8%) patients. These included chronic cystoid macular oedema in 4 (19%) patients, epiretinal membrane (ERM) in 9 (42.9%), macular chorioretinal scar in 5 (23.8%), advanced glaucomatous optic neuropathy in 2 (9.5%) and disciform macular scar in 1 (4.7%).

Preoperative management

Preoperatively, the inflammation had been controlled for a minimum of 3 months. In all patients with chronic anterior uveitis and three with posterior uveitis, surgery was undertaken when the anterior chamber activity had been reduced by treatment to the lowest possible level. Patients with previously documented macular oedema, disease activity within the 3 months before operation or those with a poor outcome in the first eye due to macular oedema or postoperative uveitis were given systemic corticosteroids (n = 58, 57%) either orally, as 40 mg of prednisolone for 2 weeks before surgery (n = 54, 93.1%) or intravenously, as methyl‐prednisolone 500 mg on the day of surgery (n = 4, 6.9%).

Phacoemulsification

Phacoemulsification was performed by a consultant or a fellow (n = 81, 80.2%) or a resident (n = 20, 19.8%) attached to the uveitis service. Manual pupillary dilatation was necessary in 7 (6.9%) patients who had significant posterior synechiae. That was carried out using either iris hooks (n = 6, 5.9%) or sphincterotomy (n = 1, 0.9%). Minimal hyphaema occurred in the latter case as well as in 3 (3.9%) patients with Fuchs' heterochromic cyclitis. Posterior capsular rupture occurred in 1 (0.9%) patient and required anterior vitrectomy.

One of five types of IOL was implanted inside the capsular bag: silicone, either plate‐haptic (C10/11UB; Chiron, Bausch & Lomb, California, USA; n = 32, 31.7%) or three‐piece model (SI30NB or SI40; Advanced Medical Optics or LI41U; Iolab, California, USA; n = 15, 14.8%); hydrophobic acrylic (Acrysof MA60U; Alcon Lab, Texas, USA; n = 24, 23.8%); polymethylmethacrylate (PMMA; MC550; Bausch & Lomb; n = 21, 20.8%); or hydrogel (Hydroview, H60M; Bausch & Lomb; n = 9, 8.9%). A hydrophobic acrylic IOL (Acrysof MA60U; Alcon Lab) was successfully placed within the remnants of the capsular bag in a patient who had had capsular rupture. Corneal sutures were required in 23 (23%) patients to secure either a large incision in those who had PMMA implants (n = 21) or a leaking wound (n = 2). Subconjunctival antibiotics (cefuroxime 125 mg or gentamicin 20 mg) and corticosteroids (betamethasone 4 mg) were injected at the end of the procedure.

Postoperative management

Patients were prescribed G dexamethsone 0.1% or G methylprednisolone acetate 1% and G chloramphenicol, gradually withdrawing over 4–6 weeks. All patients were reviewed within 48 h and subsequent visits were determined according to clinical need. Preoperative prophylactic oral prednisolone was gradually tapered and stopped over 8 weeks.

Two of the patients (1.9%) with sarcoidosis‐related posterior uveitis required vitrectomy for persistent floaters and retinal detachment 1 and 4 years postoperatively.

Outcome and statistical analysis

The main outcomes were BCVA, the rate of doubling of the visual angle (loss of [gt-or-equal, slanted]3 logMAR lines) over the follow‐up time, the development of uveitis or macular oedema within 3 months and the development of PCO that required neodymium‐doped yttrium aluminium garnet (Nd:YAG) capsulotomy at any time during follow‐up. The 3‐month follow‐up period was chosen as episodes of uveitis or macular oedema occurring at that time were more likely to be related to surgery than to the natural course of the disease.

Postoperative uveitis was defined clinically as any inflammatory episode within 3 months after surgery that required additional intensive topical or systemic anti‐inflammatory or immunosuppressive treatment in the presence of symptoms of pain and anterior chamber flare and/or cells. Postoperative macular oedema was defined as the development of clinically or angiographically identifiable retinal thickening or cystoid macular oedema, especially if associated with symptoms of blurred vision or with reduced visual acuity and if it required systemic or orbital floor corticosteroid treatment within the same period. Later episodes of uveitis or macular oedema were termed “recurrent”. PCO was considered clinically significant if it had led to symptoms of blurred vision or glare, reduced visual acuity or impaired posterior segment view and required Nd:YAG capsulotomy.

SPSS V.9 for Windows software was used for the statistical analysis. The paired t test was used to compare preoperative and postoperative visual acuity and survival table analysis was used to derive the cumulative probability of visual loss during the follow‐up time. Logrank and χ2 tests were used to identify potential risk factors, and multivariate backward regression models were constructed to identify the independent factors associated with the outcome of interest. A variable was included in the multivariate model if it had a p value of <0.2 on the bivariate analysis or if known from previous studies to affect the outcome of interest. A p value of <0.05 was considered significant.

Results

Patient characteristics

Table 11 lists the demographic and clinical features of the patients. In all, 101 eyes of 101 patients were included; 43 (43%) patients were male. The mean (range) age of the patients was 52.8 (14.1–88.2) years and the mean (range) follow‐up time was 23.4 (3–79.5) months.

Visual outcome

A significant improvement in the mean logMAR BCVA was observed at the first postoperative (within 48 h of surgery) and final visits (p<0.001; fig 11).). At the first postoperative visit, 65 (64.4%) patients had [gt-or-equal, slanted]2 Snellen's lines of visual improvement, with 58 (57.5%) having 6/12 or better. At the final visit, 72 (71.3%) patients had [gt-or-equal, slanted]2 lines of visual improvement, with 78 (77.2%) having 6/12 or better.

figure bj114801.f1
Figure 1 Error bar chart of the preoperative, postoperative and final best‐corrected visual acuity. Each error bar represents the mean visual acuity (the mid‐point) and the CI. It shows significantly improved visual acuity at the ...

Over the 6 years of follow‐up, the cumulative probability of survival for the achieved postoperative acuity (avoiding loss of one line or doubling of visual angle) steadily decreased. By the end of the follow‐up time, the probability of doubling of the visual angle was 52% (table 22 and fig 22).). A Cox multivariate analysis model (table 33)) identified preoperative macular or optic nerve lesions as independently associated with increased rate of doubling of the visual angle over the follow‐up time (HR (95% CI) 4.49 (1.41 to 14.29); p = 0.01).

figure bj114801.f2
Figure 2 Kaplan–Meyer curve of the cumulative (Cum) probability of survival for doubling of visual angle (avoiding doubling of the visual angle) over the follow‐up time.
Table thumbnail
Table 2 Survival table of the probability of maintaining visual acuity over the follow‐up time
Table thumbnail
Table 3 Cox multivariate regression analysis of the factors associated with doubling of the visual angle over the follow‐up time

Postoperative uveitis

Recurrence of uveitis occurred in 22 (21.8%) patients during the postoperative follow‐up period. In all, 15 (68.2%) patients presented with postoperative uveitis (ie, within 3 months) and the time to presentation ranged between 2 and 87 days (median 14 days). A multivariate logistic model revealed that female gender (OR (95% CI) 6.21 (1.41 to 27.43)) and the presence of synechiae (OR (95% CI) 8.43 (1.09 to 65.41)) were independently associated with an increased likelihood of developing postoperative uveitis within 3 months (table 44).

Table thumbnail
Table 4 Logistic regression analysis of the factors affecting the development of postoperative uveitis and macular oedema within 3 months

Treatment of postoperative uveitis included either intensive topical corticosteroids (dexamethasone 0.1% or prednisolone acetate 1%; n = 10, 45.5%), periocular injection of methylprednisolone 40 mg or triamcinolone 40 mg (n = 5, 22.7%), oral prednisolone (40–80 mg; n = 7, 31.8%) or a combination of both periocular and oral corticosteroids (n = 5, 22.7%). Azathioprine was added to the corticosteroids in a patient with Behçet's disease (4.5%) and intracameral injection of recombinant tissue plasminogen activator was given to 3 (13.6%) patients with fibrinous anterior uveitis.

Macular oedema

Macular oedema developed in 21 (20.8%) patients, 8 (38.1%) of whom presented within 3 months; the time to presentation ranged between 9 and 51 days (median 29 days). A multivariate logistic model revealed that patients who developed postoperative uveitis within 3 months were more likely to have macular oedema (OR (95% CI) 7.45 (1.63 to 34.16); table 44).

Macular oedema was treated with periocular (n = 10) or oral corticosteroids (n = 5) as above. Topical non‐steroidal anti‐inflammatory drugs and/or oral acetazolamide were also used in four patients. Two patients with macular thickening diagnosed clinically without concurrent uveitis and no change in visual acuity were followed up conservatively and showed spontaneous resolution of the macular thickening within 6 weeks.

PCO and Nd:YAG capsulotomy

PCO was the most common complication during the follow‐up period, occurring in 39 (38.6%) patients, 33 (84.6%) of whom required Nd:YAG capsulotomy. The time to capsulotomy ranged from 1.5 to 42.3 months (median 10.8 months). A Cox multivariate regression model revealed that capsulotomy was required at a higher rate in patients aged [less-than-or-eq, slant]55 years and in patients who had hydrogel IOLs (HR (95% CI) 3.74 (1.05 to 13.33)), and at a lower rate in patients who had plate‐haptic silicone (HR (95% CI) 0.23 (0.08 to 0.62)) and three‐piece silicone IOLs (HR (95% CI) 0.18 (0.05 to 0.71)) and in those who were given prophylactic systemic corticosteroids preoperatively (HR (95% CI) 0.24 (0.11 to 0.60); table 55).). Within 3 months of Nd:YAG capsulotomy, 1 (3%) patient developed macular oedema and was treated with periocular injection of depomedrone 40 mg.

Table thumbnail
Table 5 Cox multivariate regression analysis of the factors affecting the rate of neodymium‐doped yttrium aluminium garnet capsulotomy

Other complications

Early rise in intraocular pressure

Rise in intraocular pressure (IOP) requiring treatment occurred within the first 2 days in 6 (5.9%) patients. Four of these patients were treated with acetazolamide + topical β‐blocking agents for 2–7 days. One patient, who was on topical treatment for glaucoma before operation, needed trabeculectomy 6 weeks later for uncontrolled IOP. Another patient had a persistent rise in IOP secondary to anterior uveitis due to residual cortical lens matter that required removal 1 week after surgery and resulted in the resolution of the increased IOP.

Epiretinal membrane

A macular ERM was noted in a total of 17 (16.8%) patients, including 8 (7.9%) patients in whom it was noted for the first time during the follow‐up period.

Anterior lens deposits

In all, 3 (3%) patients developed significant deposits on the anterior lens surface that were removed with Nd:YAG laser. All the patients had plate‐haptic silicone IOLs and developed postoperative uveitis within 3 months. The procedure was uneventful and led to 1–2 lines of visual improvement in two of them.

Discussion

In this study, we found that phacoemulsification in patients with uveitis led to a significant improvement in BCVA (p<0.001). This is in agreement with other studies that reported short‐ and long‐term visual improvement of [gt-or-equal, slanted]2 lines in up to 93% of patients.4,5,6,13 Survival table analysis showed, however, that over 6 years of follow‐up, the cumulative probability of experiencing doubling of the visual angle was 52% (table 22 and fig 22),), and multivariate analysis showed that the presence of preoperative macular or optic nerve lesions was an independent predictor for increased rate of this visual loss (table 33).

Postoperative complications included postoperative uveitis (21.8%), macular oedema (20.8%), posterior capsule opacification (38.6%), ERM (7.9%), early rise in IOP (5.9%) and IOL deposits (3%). Estafanous et al,5 in a retrospective study of 32 patients with an average follow‐up of 20 months, reported recurrence of uveitis in 41%, macular oedema in 15%, ERM in 15% and PCO in 62% of patients. In another study by Suresh and Jones,6 a similar prevalence of postoperative uveitis (36%) but lower prevalence of macular oedema (2%) was reported during an average follow‐up of 24.1 months. The differences in the prevalence of complications between our study and these studies may be related to differences in the definition of complications or in the patient populations. The reported prevalence of these complications is higher in studies on extracapsular cataract extraction than in this study. Krishna et al2 showed that postoperative uveitis, macular oedema and PCO occurred in 53%, 56% and 58% of patients, respectively, over a mean follow‐up of 81.4 months. Although the longer follow‐up might have contributed to the larger percentages in that study, Okhravi et al3 reported 34%, 20% and 32% of postoperative uveitis, macular oedema and PCO, respectively, over a shorter period of follow‐up (mean 10.2 months). The smaller incision and reduced uveal trauma in phacoemulsification are known to decrease early postoperative inflammation14 and to induce less blood–aqueous barrier damage,15,16,17,18,19 both of which are linked to the development of macular oedema.20 Also, the improved cortical lens matter removal and the use of more biocompatible, better designed IOLs are important factors in reducing the PCO rate with phacoemulsification.15,16,17,21,22

Multivariate analysis (table 44)) revealed that female gender and the presence of significant synechiae were associated with the development of postoperative uveitis within 3 months. Although the relationship between gender and the development of postoperative uveitis was not clear, the relationship to the presence of significant posterior synechiae was hardly surprising. Previous studies have established that uveal trauma stimulates the release of prostaglandins, which elicit a uveal inflammatory response.23 Also, there was a significant association between the development of postoperative uveitis and the development of macular oedema, which has been suggested in other studies in patients with and without uveitis.3,20 This suggests that preoperative prophylactic or postoperative intensive topical anti‐inflammatory medications should be liberally used in patients at risk for, or those who actually develop, postoperative inflammation to ensure adequate control of any postoperative inflammation and, therefore, perhaps reduce the risk of developing macular oedema.

In all, 33 (32.7%) of our patients underwent Nd:YAG capsulotomy for clinically significant PCO. The independent factors associated with increased rate of Nd:YAG capsulotomy during the follow‐up period (table 55)) were age [less-than-or-eq, slant]55 years and hydrogel IOLs; whereas plate‐haptic and three‐piece silicone IOLs, as compared with PMMA IOLs, and the use of prophylactic corticosteroids were associated with a decreased rate.

The increased risk of Nd:YAG capsulotomy in association with hydrogel implants has been shown before in patients with24 and without uveitis,25,26 and has been ascribed to its increased water content (18–30%) in contrast to hydrophobic acrylic (<2%), silicone and PMMA implants (both <1%).27,28 However, although plate‐haptic silicone IOLs were associated with a reduced risk of Nd:YAG capsulotomy in contrast to PMMA, three patients developed visually significant deposits on the anterior lens surface that required Nd:YAG laser treatment. Previous studies have also found that these implants were associated with an increased frequency of anterior capsular contraction and IOL subluxation.29,30,31,32,33 Also, the increased affinity of silicone implants to adhere to silicone oil34 makes its material generally less favourable in patients with uveitis. Although we could not identify any significant effect in relation to hydrophobic acrylic IOLs, a recent randomised trial13 showed that they had better postoperative inflammatory indices and lower PCO in patients with uveitis.

The effect of prophylactic corticosteroids in reducing the PCO rate has not been shown previously. This effect may be related to the inhibitory action of corticosteroids on lens epithelial cell proliferation as shown in in vitro studies35,36 or to an indirect effect through inhibition of the uveal inflammatory response.7

The results of this study should be carefully interpreted in light of its design and patient population. In retrospective studies, potential bias cannot always be completely eliminated, but by including all possible preoperative and surgery‐related covariates in the multivariate analysis, we believe that the bias was significantly reduced. The three units in this study are tertiary referral units whose patient population is usually skewed towards those with more severe forms of uveitis and those with more uveitis‐related vision‐threatening complications. Therefore, the results are likely to be even better in secondary or community‐based eye centres.

In conclusion, our study highlighted some of the outcome features of phacoemulsification in patients with uveitis, which should help in patient counselling and in planning their perioperative management. Although most patients achieve significant visual improvement, there seems to be a tendency for visual loss over the follow‐up time, especially in patients with pre‐existent macular or optic nerve lesions. Identifying patients who are at risk for the development of postoperative complications and using a regimen of frequent follow‐up, judicious use of either preoperative prophylactic or postoperative systemic or topical corticosteroids, and carefully selecting the IOL type should help minimise the incidence of complications and improve the overall outcome in these patients.

Acknowledgements

We thank Miss Michelle Bradley at the Department of Public Health and Primary Care, University of Cambridge for the statistical consultation and advice and Ratna Khan for the help with the data retrieval.

Abbreviations

BCVA - best‐corrected visual acuity

ERM - epiretinal membrane

IOL - intraocular lens

IOP - intraocular pressure

logMAR - log minimum angle of resolution

Nd:YAG - neodymium‐doped yttrium aluminium garnet

PCO - posterior capsular opacification

PMMA - polymethylmethacrylate

Footnotes

Funding: Scholarship fund to MAE from Tanta University, Tanta, Egypt.

Competing interests: None declared.

This paper was presented at the European Association of Vision and Eye Research (EVER) annual meeting, Vilamoura, Portugal, September, 2004.

References

1. Foster R E, Lowder C Y, Meisler D M. et al Extracapsular cataract extraction and posterior chamber intraocular lens implantation in uveitis patients. Ophthalmology 1992. 991234–1241.1241 [PubMed]
2. Krishna R, Meisler D M, Lowder C Y. et al Long‐term follow‐up of extracapsular cataract extraction and posterior chamber intraocular lens implantation in patients with uveitis. Ophthalmology 1998. 1051765–1769.1769 [PubMed]
3. Okhravi N, Lightman S L, Towler H M. Assessment of visual outcome after cataract surgery in patients with uveitis. Ophthalmology 1999. 106710–722.722 [PubMed]
4. Rauz S, Stavrou P, Murray P I. Evaluation of foldable intraocular lenses in patients with uveitis. Ophthalmology 2000. 107909–919.919 [PubMed]
5. Estafanous M F, Lowder C Y, Meisler D M. et al Phacoemulsification cataract extraction and posterior chamber lens implantation in patients with uveitis. Am J Ophthalmol 2001. 131620–625.625 [PubMed]
6. Suresh P S, Jones N P. Phacoemulsification with intraocular lens implantation in patients with uveitis. Eye 2001. 15621–628.628 [PubMed]
7. Meacock W R, Spalton D J, Bender L. et al Steroid prophylaxis in eyes with uveitis undergoing phacoemulsification. Br J Ophthalmol 2004. 881122–1124.1124 [PMC free article] [PubMed]
8. Heger H, Drolsum L, Haaskjold E. Cataract surgery with implantation of IOL in patients with uveitis. Acta Ophthalmol (Copenh) 1994. 72478–482.482 [PubMed]
9. Dana M R, Chatzistefanou K, Schaumberg D A. et al Posterior capsule opacification after cataract surgery in patients with uveitis. Ophthalmology 1997. 1041387–1393.1393 [PubMed]
10. Sakamoto M, Akazawa K, Nishioka Y. et al Prognostic factors of vision in patients with Behçet disease. Ophthalmology 1995. 102317–321.321 [PubMed]
11. Dana M R, Merayo‐Lloves J, Schaumberg D A. et al Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 1996. 1031846–1853.1853 [PubMed]
12. Bloch‐Michel E, Nussenblatt R B. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987. 103234–235.235 [PubMed]
13. Alio J L, Chipont E, BenEzra D. et al Comparative performance of intraocular lenses in eyes with cataract and uveitis. J Cataract Refract Surg 2002. 282096–2108.2108 [PubMed]
14. Oshika T, Yoshimura K, Miyata N. Postsurgical inflammation after phacoemulsification and extracapsular extraction with soft or conventional intraocular lens implantation. J Cataract Refract Surg 1992. 18356–361.361 [PubMed]
15. Hollick E J, Spalton D J, Ursell P G. et al Biocompatibility of poly (methyl methacrylate), silicone, and AcrySof intraocular lenses: randomized comparison of the cellular reaction on the anterior lens surface. J Cataract Refract Surg 1998. 24361–366.366 [PubMed]
16. Majima K. An evaluation of the biocompatibility of intraocular lenses. Ophthalmic Surg Lasers 1996. 27946–951.951 [PubMed]
17. McCulley J P. Biocompatibility of intraocular lenses. Eye Contact Lens 2003. 29155–163.163 [PubMed]
18. Pande M V, Spalton D J, Kerr‐Muir M G. et al Postoperative inflammatory response to phacoemulsification and extracapsular cataract surgery: aqueous flare and cells. J Cataract Refract Surg 1996. 22(Suppl 1)770–774.774 [PubMed]
19. Chee S P, Ti S E, Sivakumar M. et al Postoperative inflammation: extracapsular cataract extraction versus phacoemulsification. J Cataract Refract Surg 1999. 251280–1285.1285 [PubMed]
20. Ursell P G, Spalton D J, Whitcup S M. et al Cystoid macular edema after phacoemulsification: relationship to blood‐aqueous barrier damage and visual acuity. J Cataract Refract Surg 1999. 251492–1497.1497 [PubMed]
21. Apple D J, Peng Q, Visessook N. et al Eradication of posterior capsule opacification: documentation of a marked decrease in Nd:YAG laser posterior capsulotomy rates noted in an analysis of 5416 pseudophakic human eyes obtained postmortem. Ophthalmology 2001. 108505–518.518 [PubMed]
22. Amon M, Menapace R. In vivo documentation of cellular reactions on lens surfaces for assessing the biocompatibility of different intraocular implants. Eye 1994. 8(Pt 6)649–656.656 [PubMed]
23. Bhattacherjee P. Prostaglandins and inflammatory reactions in the eye. Methods Find Exp Clin Pharmacol 1980. 217–31.31 [PubMed]
24. Abela‐Formanek C, Amon M, Schauersberger J. et al Results of hydrophilic acrylic, hydrophobic acrylic, and silicone intraocular lenses in uveitic eyes with cataract: comparison to a control group. J Cataract Refract Surg 2002. 281141–1152.1152 [PubMed]
25. Hollick E J, Spalton D J, Ursell P G. et al Posterior capsular opacification with hydrogel, polymethylmethacrylate, and silicone intraocular lenses: two‐year results of a randomized prospective trial. Am J Ophthalmol 2000. 129577–584.584 [PubMed]
26. Javdani S M, Huygens M M, Callebaut F. Neodymium: YAG capsulotomy rates after phacoemulsification with hydrophobic and hydrophilic acrylic intraocular lenses. Bull Soc Belge Ophtalmol 2002. 13–17.17 [PubMed]
27. Doan K T, Olson R J, Mamalis N. Survey of intraocular lens material and design. Curr Opin Ophthalmol 2002. 1324–29.29 [PubMed]
28. Tehrani M, Dick H B, Wolters B. et al Material properties of various intraocular lenses in an experimental study. Ophthalmologica 2004. 21857–63.63 [PubMed]
29. Davison J A. Capsule contraction syndrome. J Cataract Refract Surg 1993. 19582–589.589 [PubMed]
30. Akerele T, Minasian M, Little B. et al Posterior dislocation of Staar plate haptic silicone lenses following Nd:YAG capsulotomy. Eye 1999. 13(Pt 5)700–702.702 [PubMed]
31. Tuft S J, Talks S J. Delayed dislocation of foldable plate‐haptic silicone lenses after Nd:YAG laser anterior capsulotomy. Am J Ophthalmol 1998. 126586–588.588 [PubMed]
32. Mamalis N, Davis B, Nilson C D. et al Complications of foldable intraocular lenses requiring explantation or secondary intervention‐2003 survey update. J Cataract Refract Surg 2004. 302209–2218.2218 [PubMed]
33. Oner F H, Saatci O A, Sarioglu S. et al Interaction of intraocular lenses with various concentrations of silicone oil: an experimental study. Ophthalmologica 2003. 217124–128.128 [PubMed]
34. Apple D J, Federman J L, Krolicki T J. et al Irreversible silicone oil adhesion to silicone intraocular lenses. A clinicopathologic analysis. Ophthalmology 1996. 1031555–1561.1561 [PubMed]
35. McDonnell P J, Krause W, Glaser B M. In vitro inhibition of lens epithelial cell proliferation and migration. Ophthalmic Surg 1988. 1925–30.30 [PubMed]
36. Cortina P, Gomez‐Lechon M J, Navea A. et al Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture. Graefes Arch Clin Exp Ophthalmol 1997. 235180–185.185 [PubMed]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group